Switch to:
Also traded in: Austria, Brazil, Chile, Germany, Mexico, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.54
GILD's Cash-to-Debt is ranked lower than
87% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. GILD: 0.54 )
Ranked among companies with meaningful Cash-to-Debt only.
GILD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15  Med: 1.74 Max: N/A
Current: 0.54
Equity-to-Asset 0.35
GILD's Equity-to-Asset is ranked lower than
83% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. GILD: 0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
GILD' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.62 Max: 0.98
Current: 0.35
0.21
0.98
Interest Coverage 16.83
GILD's Interest Coverage is ranked lower than
82% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GILD: 16.83 )
Ranked among companies with meaningful Interest Coverage only.
GILD' s Interest Coverage Range Over the Past 10 Years
Min: 11.11  Med: 34.31 Max: 165.23
Current: 16.83
11.11
165.23
Piotroski F-Score: 5
Altman Z-Score: 3.77
Beneish M-Score: -3.04
WACC vs ROIC
7.06%
41.49%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 57.55
GILD's Operating Margin % is ranked higher than
97% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. GILD: 57.55 )
Ranked among companies with meaningful Operating Margin % only.
GILD' s Operating Margin % Range Over the Past 10 Years
Min: 40.39  Med: 50.27 Max: 68
Current: 57.55
40.39
68
Net Margin % 43.42
GILD's Net Margin % is ranked higher than
96% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. GILD: 43.42 )
Ranked among companies with meaningful Net Margin % only.
GILD' s Net Margin % Range Over the Past 10 Years
Min: 26.72  Med: 37.34 Max: 55.48
Current: 43.42
26.72
55.48
ROE % 74.22
GILD's ROE % is ranked higher than
99% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. GILD: 74.22 )
Ranked among companies with meaningful ROE % only.
GILD' s ROE % Range Over the Past 10 Years
Min: 29.75  Med: 50.37 Max: 106.64
Current: 74.22
29.75
106.64
ROA % 23.49
GILD's ROA % is ranked higher than
97% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. GILD: 23.49 )
Ranked among companies with meaningful ROA % only.
GILD' s ROA % Range Over the Past 10 Years
Min: 13.45  Med: 29.12 Max: 42.28
Current: 23.49
13.45
42.28
ROC (Joel Greenblatt) % 561.81
GILD's ROC (Joel Greenblatt) % is ranked higher than
98% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. GILD: 561.81 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GILD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 161.64  Med: 183.96 Max: 595.52
Current: 561.81
161.64
595.52
3-Year Revenue Growth Rate 50.20
GILD's 3-Year Revenue Growth Rate is ranked higher than
87% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. GILD: 50.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GILD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 41.7 Max: 162.8
Current: 50.2
0
162.8
3-Year EBITDA Growth Rate 70.30
GILD's 3-Year EBITDA Growth Rate is ranked higher than
93% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. GILD: 70.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GILD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -29.8  Med: 38.05 Max: 116.7
Current: 70.3
-29.8
116.7
3-Year EPS without NRI Growth Rate 76.40
GILD's 3-Year EPS without NRI Growth Rate is ranked higher than
95% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. GILD: 76.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
GILD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -19.7  Med: 30.35 Max: 143.5
Current: 76.4
-19.7
143.5
» GILD's 30-Y Financials

Financials (Next Earnings Date: 2017-07-26)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

GILD Guru Trades in Q3 2016

First Eagle Investment 49,700 sh (+220.65%)
Jeremy Grantham 1,165,716 sh (+175.52%)
Jim Simons 1,947,048 sh (+80.39%)
Jeff Auxier 4,782 sh (+60.36%)
Jerome Dodson 350,000 sh (+32.08%)
Zeke Ashton 25,000 sh (+16.28%)
Murray Stahl 11,550 sh (+14.93%)
Lee Ainslie 7,880 sh (+12.25%)
John Rogers 1,532,528 sh (+6.18%)
T Rowe Price Equity Income Fund 1,425,000 sh (+3.64%)
Eaton Vance Worldwide Health Sciences Fund 635,263 sh (+94.21%)
Ronald Muhlenkamp 7,500 sh (unchged)
Julian Robertson 38,511 sh (unchged)
First Eagle Investment 300 sh (unchged)
Dodge & Cox 3,750 sh (unchged)
John Burbank 5,000,000 sh (unchged)
David Carlson 730,000 sh (unchged)
Ken Fisher 444,529 sh (-0.44%)
John Buckingham 62,994 sh (-1.03%)
Ronald Muhlenkamp 214,495 sh (-1.15%)
David Dreman 21,855 sh (-3.06%)
Pioneer Investments 3,293,651 sh (-4.95%)
Joel Greenblatt 923,534 sh (-9.11%)
Ray Dalio 315,272 sh (-15.85%)
NWQ Managers 81,896 sh (-24.38%)
Mario Gabelli 12,414 sh (-65.34%)
Steven Cohen 141,000 sh (-78.61%)
Paul Tudor Jones 2,800 sh (-79.64%)
John Burbank 3,224 sh (-99.56%)
» More
Q4 2016

GILD Guru Trades in Q4 2016

Tom Gayner 14,000 sh (New)
Paul Tudor Jones 11,401 sh (+307.18%)
Jim Simons 5,274,948 sh (+170.92%)
Jerome Dodson 490,000 sh (+40.00%)
Jeff Auxier 5,477 sh (+14.53%)
Murray Stahl 13,000 sh (+12.55%)
Joel Greenblatt 1,025,203 sh (+11.01%)
Lee Ainslie 8,520 sh (+8.12%)
John Rogers 1,584,199 sh (+3.37%)
Ken Fisher 455,496 sh (+2.47%)
Mario Gabelli 12,414 sh (unchged)
Ronald Muhlenkamp 14,800 sh (unchged)
Julian Robertson 38,511 sh (unchged)
T Rowe Price Equity Income Fund 1,425,000 sh (unchged)
First Eagle Investment 300 sh (unchged)
First Eagle Investment 49,700 sh (unchged)
David Carlson 730,000 sh (unchged)
Steven Cohen Sold Out
John Burbank Sold Out
Ronald Muhlenkamp 212,995 sh (-0.70%)
David Dreman 20,724 sh (-5.18%)
John Buckingham 59,446 sh (-5.63%)
Dodge & Cox 3,250 sh (-13.33%)
Zeke Ashton 21,000 sh (-16.00%)
Pioneer Investments 2,722,308 sh (-17.35%)
Jeremy Grantham 874,684 sh (-24.97%)
NWQ Managers 61,056 sh (-25.45%)
Ray Dalio 80,272 sh (-74.54%)
Eaton Vance Worldwide Health Sciences Fund 550,067 sh (-13.41%)
» More
Q1 2017

GILD Guru Trades in Q1 2017

Charles Brandes 108,756 sh (New)
John Hussman 50,000 sh (New)
Steven Cohen 566,100 sh (New)
Tom Gayner 27,000 sh (+92.86%)
Paul Tudor Jones 20,709 sh (+81.64%)
T Rowe Price Equity Income Fund 2,560,000 sh (+79.65%)
Jim Simons 7,707,248 sh (+46.11%)
Jerome Dodson 601,000 sh (+22.65%)
Jeff Auxier 6,677 sh (+21.91%)
First Eagle Investment 59,700 sh (+20.12%)
Joel Greenblatt 1,212,036 sh (+18.22%)
John Rogers 1,800,201 sh (+13.63%)
Mario Gabelli 14,080 sh (+13.42%)
Lee Ainslie 9,460 sh (+11.03%)
John Buckingham 63,635 sh (+7.05%)
Ronald Muhlenkamp 225,725 sh (+5.98%)
Murray Stahl 13,600 sh (+4.62%)
Ronald Muhlenkamp 28,600 sh (unchged)
Julian Robertson 38,511 sh (unchged)
First Eagle Investment 300 sh (unchged)
Dodge & Cox 3,250 sh (unchged)
Steven Cohen 28,700 sh (unchged)
David Carlson 730,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 550,067 sh (unchged)
Zeke Ashton Sold Out
Ray Dalio Sold Out
Ken Fisher 451,634 sh (-0.85%)
David Dreman 20,174 sh (-2.65%)
NWQ Managers 52,811 sh (-13.50%)
Pioneer Investments 1,898,063 sh (-30.28%)
Jeremy Grantham 37,400 sh (-95.72%)
» More
Q2 2017

GILD Guru Trades in Q2 2017

Manning & Napier Advisors, Inc 214,432 sh (New)
T Rowe Price Equity Income Fund 3,270,900 sh (+27.77%)
Jerome Dodson 646,000 sh (+7.49%)
Ken Fisher 460,155 sh (+1.89%)
» More
» Details

Insider Trades

Latest Guru Trades with GILD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:CELG, NAS:BIIB, NAS:AMGN, NAS:REGN, NAS:VRTX, NAS:ALXN, NAS:INCY, NAS:BMRN, NAS:EXEL, NAS:SGEN, NAS:TSRO, NAS:ALNY, NAS:BIVV, NAS:IONS, NAS:UTHR, NAS:KITE, NAS:CLVS, NAS:TECH, NAS:NBIX, NAS:BLUE » details
Traded in other countries:GILD.Austria, GILD34.Brazil, GILD.Chile, GIS.Germany, GILD.Mexico, GILD.Switzerland,
Headquarter Location:USA
Gilead Sciences Inc is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of the recently approved combination regimen Harvoni.

Guru Investment Theses on Gilead Sciences Inc

Jerome Dodson Comments on Gilead - Jan 25, 2017

Our other laggard was Gilead (NASDAQ:GILD), a biotechnology firm that makes therapies for HIV and Hepatitis C. Gilead sliced 98 basis points off the Fund’s return, as its stock declined 29.2%, from $101.19 to $71.61. The stock dropped due to weakness in the Hepatitis C business, as pricing came under pressure due to increased competition, and the patient population fell because Gilead’s drugs cure patients of this damaging disease. The stock is on the bargain table, and the company has a strong balance sheet and a proven track record of innovation, so we increased our position throughout the year.



From the Parnassus Fund fourth quarter 2016 commentary.



Check out Jerome Dodson latest stock trades

Jerome Dodson Comments on Gilead - Jul 26, 2016

Gilead (NASDAQ:GILD), a biotechnology firm that makes therapies for HIV and hepatitis C, sliced 21 basis points off the Fund’s return, as its stock declined 9.2% from $91.86 to $83.42. The company’s underperformance was driven by weakness in its hepatitis C business, as pricing came under pressure due to increased competition. Given Gilead’s proven track record of innovation and its strong balance sheet, we believe the company has many opportunities, not only to maintain leadership in HIV and hepatitis C, but also to expand its portfolio into new therapeutic areas.


From Jerome Dodson (Trades, Portfolio)'s Parnassus Fund second quarter 2016 commentary.

Check out Jerome Dodson latest stock trades

John Rogers Comments on Gilead Sciences Inc. - Dec 02, 2015

Biotechnology leader Gilead Sciences, Inc. (NASDAQ:GILD) dropped -15.90% on recent concerns over drug pricing. Gilead actually reported quarterly earnings that were better than expected. We continue to hold the shares, based on our belief that the market is overly focused on pricing and underestimating future sales that we think are likely to grow.





From John Rogers (Trades, Portfolio) 3rd quarter commentary on the Ariel Global Fund.

Check out John Rogers latest stock trades

Top Ranked Articles about Gilead Sciences Inc

Spring Bank Pharmaceuticals' Hepatitis B Results in Context Here's a look at where the company's latest data fit into the hepatitis B space as a whole
Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) announced positive initial Phase II results for its new antiviral hepatitis B (HBV) treatment SB-9200. Shares have recorded all-time highs, up as much as 28% on the news. Read more...
Stocks That Fell to 3-Year Lows in the Week of May 12 Gilead Sciences, Ford Motor, Taubman Centers and Dillard's have declined to their respective lows
Gilead Sciences Inc. (NASDAQ:GILD), Ford Motor Co. (NYSE:F), Taubman Centers Inc. (NYSE:TCO) and Dillard's Inc. (NYSE:DDS) have declined to their three-year lows. Read more...
Charles Brandes Invests in Health Care in 1st Quarter Guru buys AstraZeneca, CVS, Gilead Sciences, others
Charles Brandes (Trades, Portfolio)’ Brandes Investment Partners gained 49 new holdings during the quarter. Among the purchases were several health care stocks. His three largest new health care holdings are AstraZeneca PLC (NYSE:AZN), CVS Health Corp. (NYSE:CVS) and Gilead Sciences Inc. (NASDAQ:GILD). Read more...
BetterInvesting Top 100, Reflecting the Portfolios of Main Street Investors, Rises in April and Gains 13.2 Percent Annually for Past Five Years
Jerome Dodson Keeps Buying McKesson, Axalta, Pentair Stocks the fund bought in the last 2 quarters
Jerome Dodson (Trades, Portfolio) is the founder and president of Parnassus Investments. He is the lead portfolio manager of the Parnassus Fund and the Parnassus Asia Fund and is the sole portfolio manager of the Parnassus Endeavor Fund. In both first quarter 2017 and fourth quarter 2016 the guru bought shares in the following stocks: Read more...
FDA Rejects Eli Lilly, Incyte's Commercialization Application Shares tumbled after agency did not approve the companies' rheumatoid arthritis treatment
The U.S. Food and Drug Administration did not approve the marketing application for baricitinib, a medication that Eli Lilly and Co. (NYSE:LLY) is developing with Incyte Corp. (NASDAQ:INCY) for treating patients with rheumatoid arthritis, according to a news release published through Business Wire. Read more...
Stocks That Fell to 3-Year Lows in the Week of April 14 Gilead Sciences, Target, New York Community Bancorp and Ralph Lauren fell to their three-year lows
Gilead Sciences Inc. (NASDAQ:GILD) declined to $66.51 Read more...
A Socially Conscious Guru Jerome Dodson wants companies, but they also must be 'good' companies, concerned about the environment, society beyond just shareholders and corporate governance
Special Investors Release: Covered call stock options reports for Comcast, Salesforce, Gilead Sciences, Hewlett Packard Enterprise Company, and Snap Inc.
Executive Chairman Slashes Stake in Gilead Sciences Company's market price has fallen an estimated 25% over the previous year
Insider John Martin, the executive chairman of Gilead Sciences (NASDAQ:GILD), sold 73,333 shares on March 3 for $70.38 per share according to a Form 4 filing with the securities and exchange commission Read more...

Ratios

vs
industry
vs
history
PE Ratio 7.75
GILD's PE Ratio is ranked higher than
90% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. GILD: 7.75 )
Ranked among companies with meaningful PE Ratio only.
GILD' s PE Ratio Range Over the Past 10 Years
Min: 6.67  Med: 15.37 Max: 45.49
Current: 7.75
6.67
45.49
Forward PE Ratio 8.98
GILD's Forward PE Ratio is ranked higher than
85% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. GILD: 8.98 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 7.75
GILD's PE Ratio without NRI is ranked higher than
91% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. GILD: 7.75 )
Ranked among companies with meaningful PE Ratio without NRI only.
GILD' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.67  Med: 15.28 Max: 45.49
Current: 7.75
6.67
45.49
Price-to-Owner-Earnings 6.77
GILD's Price-to-Owner-Earnings is ranked higher than
89% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. GILD: 6.77 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
GILD' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.68  Med: 13.84 Max: 74.51
Current: 6.77
5.68
74.51
PB Ratio 4.71
GILD's PB Ratio is ranked lower than
56% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. GILD: 4.71 )
Ranked among companies with meaningful PB Ratio only.
GILD' s PB Ratio Range Over the Past 10 Years
Min: 4.1  Med: 8 Max: 18.71
Current: 4.71
4.1
18.71
PS Ratio 3.38
GILD's PS Ratio is ranked higher than
80% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. GILD: 3.38 )
Ranked among companies with meaningful PS Ratio only.
GILD' s PS Ratio Range Over the Past 10 Years
Min: 2.94  Med: 6.41 Max: 12.5
Current: 3.38
2.94
12.5
Price-to-Free-Cash-Flow 6.65
GILD's Price-to-Free-Cash-Flow is ranked higher than
90% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. GILD: 6.65 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GILD' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.66  Med: 15.58 Max: 48.02
Current: 6.65
5.66
48.02
Price-to-Operating-Cash-Flow 6.35
GILD's Price-to-Operating-Cash-Flow is ranked higher than
91% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. GILD: 6.35 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GILD' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.41  Med: 14.74 Max: 45.09
Current: 6.35
5.41
45.09
EV-to-EBIT 6.31
GILD's EV-to-EBIT is ranked higher than
83% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. GILD: 6.31 )
Ranked among companies with meaningful EV-to-EBIT only.
GILD' s EV-to-EBIT Range Over the Past 10 Years
Min: -154.2  Med: 11.5 Max: 209.2
Current: 6.31
-154.2
209.2
EV-to-EBITDA 5.92
GILD's EV-to-EBITDA is ranked higher than
82% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. GILD: 5.92 )
Ranked among companies with meaningful EV-to-EBITDA only.
GILD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -189.9  Med: 10.8 Max: 168
Current: 5.92
-189.9
168
PEG Ratio 0.15
GILD's PEG Ratio is ranked higher than
99% of the 102 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. GILD: 0.15 )
Ranked among companies with meaningful PEG Ratio only.
GILD' s PEG Ratio Range Over the Past 10 Years
Min: 0.11  Med: 0.43 Max: 3.81
Current: 0.15
0.11
3.81
Shiller PE Ratio 17.03
GILD's Shiller PE Ratio is ranked higher than
88% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 44.06 vs. GILD: 17.03 )
Ranked among companies with meaningful Shiller PE Ratio only.
GILD' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.88  Med: 52.25 Max: 2078
Current: 17.03
14.88
2078
Current Ratio 2.59
GILD's Current Ratio is ranked lower than
66% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. GILD: 2.59 )
Ranked among companies with meaningful Current Ratio only.
GILD' s Current Ratio Range Over the Past 10 Years
Min: 1.09  Med: 7.06 Max: 57.67
Current: 2.59
1.09
57.67
Quick Ratio 2.41
GILD's Quick Ratio is ranked lower than
64% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. GILD: 2.41 )
Ranked among companies with meaningful Quick Ratio only.
GILD' s Quick Ratio Range Over the Past 10 Years
Min: 0.83  Med: 6.59 Max: 57.67
Current: 2.41
0.83
57.67
Days Inventory 157.84
GILD's Days Inventory is ranked lower than
59% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. GILD: 157.84 )
Ranked among companies with meaningful Days Inventory only.
GILD' s Days Inventory Range Over the Past 10 Years
Min: 148.53  Med: 221.48 Max: 276.35
Current: 157.84
148.53
276.35
Days Sales Outstanding 50.60
GILD's Days Sales Outstanding is ranked higher than
63% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. GILD: 50.60 )
Ranked among companies with meaningful Days Sales Outstanding only.
GILD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.6  Med: 69.31 Max: 84.93
Current: 50.6
50.6
84.93
Days Payable 85.60
GILD's Days Payable is ranked higher than
66% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. GILD: 85.60 )
Ranked among companies with meaningful Days Payable only.
GILD' s Days Payable Range Over the Past 10 Years
Min: 85.6  Med: 158.55 Max: 207.21
Current: 85.6
85.6
207.21

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.70
GILD's Dividend Yield % is ranked higher than
88% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 1.27 vs. GILD: 2.70 )
Ranked among companies with meaningful Dividend Yield % only.
GILD' s Dividend Yield % Range Over the Past 10 Years
Min: 0.36  Med: 2.08 Max: 3.01
Current: 2.7
0.36
3.01
Dividend Payout Ratio 0.20
GILD's Dividend Payout Ratio is ranked higher than
85% of the 131 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. GILD: 0.20 )
Ranked among companies with meaningful Dividend Payout Ratio only.
GILD' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.11  Med: 0.15 Max: 0.2
Current: 0.2
0.11
0.2
Forward Dividend Yield % 2.86
GILD's Forward Dividend Yield % is ranked higher than
89% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.26 vs. GILD: 2.86 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.70
GILD's 5-Year Yield-on-Cost % is ranked higher than
71% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 1.54 vs. GILD: 2.70 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
GILD' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.36  Med: 2.08 Max: 3.01
Current: 2.7
0.36
3.01
3-Year Average Share Buyback Ratio 5.10
GILD's 3-Year Average Share Buyback Ratio is ranked higher than
99% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. GILD: 5.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GILD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.6  Med: -3.9 Max: 6.1
Current: 5.1
-25.6
6.1

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 9.13
GILD's Price-to-Tangible-Book is ranked lower than
72% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. GILD: 9.13 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GILD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.51  Med: 8.56 Max: 214.73
Current: 9.13
1.51
214.73
Price-to-Intrinsic-Value-Projected-FCF 0.60
GILD's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
97% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. GILD: 0.60 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GILD' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.55  Med: 2.12 Max: 20.83
Current: 0.6
0.55
20.83
Price-to-Median-PS-Value 0.53
GILD's Price-to-Median-PS-Value is ranked higher than
79% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. GILD: 0.53 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GILD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.49  Med: 1.88 Max: 30
Current: 0.53
0.49
30
Price-to-Peter-Lynch-Fair-Value 0.31
GILD's Price-to-Peter-Lynch-Fair-Value is ranked higher than
99% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 1.95 vs. GILD: 0.31 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
GILD' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.29  Med: 0.93 Max: 9.13
Current: 0.31
0.29
9.13
Price-to-Graham-Number 1.77
GILD's Price-to-Graham-Number is ranked higher than
70% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. GILD: 1.77 )
Ranked among companies with meaningful Price-to-Graham-Number only.
GILD' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.64  Med: 3.46 Max: 15.78
Current: 1.77
1.64
15.78
Earnings Yield (Greenblatt) % 15.85
GILD's Earnings Yield (Greenblatt) % is ranked higher than
95% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. GILD: 15.85 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GILD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2.1  Med: 7.4 Max: 17.7
Current: 15.85
-2.1
17.7
Forward Rate of Return (Yacktman) % 69.69
GILD's Forward Rate of Return (Yacktman) % is ranked higher than
98% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 14.33 vs. GILD: 69.69 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
GILD' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.2  Med: 6.8 Max: 71
Current: 69.69
1.2
71

More Statistics

Revenue (TTM) (Mil) $29,101.00
EPS (TTM) $ 9.47
Beta0.96
Short Percentage of Float0.93%
52-Week Range $63.76 - 88.85
Shares Outstanding (Mil)1,306.73

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 24,404 22,259 20,894
EPS ($) 8.04 7.34 7.01
EPS without NRI ($) 8.04 7.34 7.01
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-9.75%
Dividends per Share ($) 1.94 2.04 1.88
» More Articles for GILD

Headlines

Articles On GuruFocus.com
10 Undervalued Stocks for the Enterprising Investor Jul 17 2017 
Spring Bank Pharmaceuticals' Hepatitis B Results in Context Jun 07 2017 
Stocks That Fell to 3-Year Lows in the Week of May 12 May 14 2017 
Charles Brandes Invests in Health Care in 1st Quarter May 11 2017 
BetterInvesting Top 100, Reflecting the Portfolios of Main Street Investors, Rises in April and Gain May 04 2017 
Jerome Dodson Keeps Buying McKesson, Axalta, Pentair Apr 25 2017 
The Better Big Pharma Stock: AbbVie or Gilead? Apr 18 2017 
FDA Rejects Eli Lilly, Incyte's Commercialization Application Apr 18 2017 
Stocks That Fell to 3-Year Lows in the Week of April 14 Apr 16 2017 
7 Stocks With Rising Revenue and EPS Apr 11 2017 

More From Other Websites
Vertex Becomes an Overnight Biotech M&A Darling Jul 20 2017
Biotech Bulletin of the Week: Gilead Sciences, Inc. (GILD), Vertex Pharmaceuticals Incorporated... Jul 20 2017
Is Gilead (GILD) Poised for a Beat This Earnings Season? Jul 20 2017
How AbbVie Could Hammer Gilead's Hepatitis C Franchise Jul 19 2017
Jefferies' Michael Yee: Still a valuation call in biotech Jul 19 2017
Gilead Sciences: Not a Game Changer Jul 19 2017
Gilead's HCV Portfolio Receives a Boost With Vosevi Approval Jul 19 2017
When It Comes To Abusive Drug Pricing, Don't Confuse Shkreli With Hep C Drugs Jul 19 2017
Four Buffett-Inspired Picks That Could Outrun The Bulls Jul 18 2017
FDA approves Gilead's drug for chronic hep C patients Jul 18 2017
Gilead Secures FDA Approval For Chronic Hepatitis C Re-Treatment Jul 18 2017
U.S. Food and Drug Administration Approves Gilead’s Vosevi™... Jul 18 2017
5 Big Pharma Stocks With the Best Drug Pipelines Jul 18 2017
5 Ways Gilead Sciences Could Spend Its Cash Hoard Jul 18 2017
Why Gilead Won't Buy Incyte and Vertex Jul 18 2017
'Stars Align' For These Biotechs To Crush Earnings Consensus Jul 17 2017
How Intangible Assets Create Value Jul 17 2017
Health-care fund manager with 20% gain this year sees good times ahead as FDA becomes ‘more... Jul 17 2017
Will the Drug Pricing Executive Order Help Big Pharma? Jul 16 2017
These 3 Charts Don't Lie: Gilead Sciences Needs an Acquisition Jul 16 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}